263 related articles for article (PubMed ID: 28505557)
1. Follow-up of patients with localized breast cancer and first indicators of advanced breast cancer recurrence: A retrospective study.
Viot J; Bachour M; Meurisse A; Pivot X; Fiteni F
Breast; 2017 Aug; 34():53-57. PubMed ID: 28505557
[TBL] [Abstract][Full Text] [Related]
2. A retrospective study of first indicators of breast cancer recurrence.
Pivot X; Asmar L; Hortobagyi GN; Theriault R; Pastorini F; Buzdar A
Oncology; 2000 Apr; 58(3):185-90. PubMed ID: 10765118
[TBL] [Abstract][Full Text] [Related]
3. [Clinical features and prognosis of patients with first-episode liver metastasis of different molecular subtypes of breast cancer].
Wu SY; Tan Y; Guan YS
Zhonghua Gan Zang Bing Za Zhi; 2016 Jun; 24(6):422-8. PubMed ID: 27465945
[TBL] [Abstract][Full Text] [Related]
4. [Elevation of serum Ca 15-3 antigen: an early indicator of distant metastasis from breast cancer. Retrospective analysis of 733 cases].
Wojtacki J; Kruszewski WJ; Sliwińska M; Kruszewska E; Hajdukiewicz W; Sliwiński W; Rolka-Stempniewicz G; Góralczyk M; Leśniewski-Kmak K
Przegl Lek; 2001; 58(6):498-503. PubMed ID: 11816740
[TBL] [Abstract][Full Text] [Related]
5. [CEA and early detection of relapse in breast cancer subtypes: Comparison with CA 15-3].
Riedinger JM; Goussot V; Desmoulins I; Lorgis V; Coutant C; Beltjens F; Lizard S; Fumoleau P
Bull Cancer; 2016 May; 103(5):434-43. PubMed ID: 26969424
[TBL] [Abstract][Full Text] [Related]
6. [Clinical characteristics and survival in the operable breast cancer patients with different molecular subtypes].
Zhang HM; Zhang BN; Xuan LX; Zhao P
Zhonghua Zhong Liu Za Zhi; 2009 Jun; 31(6):447-51. PubMed ID: 19950556
[TBL] [Abstract][Full Text] [Related]
7. Utility of C-erbB-2 in tissue and in serum in the early diagnosis of recurrence in breast cancer patients: comparison with carcinoembryonic antigen and CA 15.3.
Molina R; Jo J; Zanón G; Filella X; Farrus B; Muñoz M; Latre ML; Pahisa J; Velasco M; Fernandez P; Estapé J; Ballesta AM
Br J Cancer; 1996 Oct; 74(7):1126-31. PubMed ID: 8855986
[TBL] [Abstract][Full Text] [Related]
8. [Treatment outcomes and clinicopathologic characteristics of advanced triple-negative breast cancer patients].
Zhang P; Xu BH; Ma F; Li Q; Yuan P; Wang JY; Zhang P
Zhonghua Zhong Liu Za Zhi; 2011 May; 33(5):381-4. PubMed ID: 21875471
[TBL] [Abstract][Full Text] [Related]
9. Tumor marker CA 15-3 in breast cancer patients.
Fejzić H; Mujagić S; Azabagić S; Burina M
Acta Med Acad; 2015; 44(1):39-46. PubMed ID: 26062696
[TBL] [Abstract][Full Text] [Related]
10. Outcome following local-regional recurrence in women with early-stage breast cancer: impact of biologic subtype.
Braunstein LZ; Niemierko A; Shenouda MN; Truong L; Sadek BT; Abi Raad R; Wong JS; Punglia RS; Taghian AG; Bellon JR
Breast J; 2015; 21(2):161-7. PubMed ID: 25559656
[TBL] [Abstract][Full Text] [Related]
11. Ca 15-3 in the follow-up of localised breast cancer: a prospective study.
Kokko R; Holli K; Hakama M
Eur J Cancer; 2002 Jun; 38(9):1189-93. PubMed ID: 12044504
[TBL] [Abstract][Full Text] [Related]
12. Pilot randomised study of early intervention based on tumour markers in the follow-up of patients with primary breast cancer.
Mathew J; Prinsloo P; Agrawal A; Gutteridge E; Marenah C; Robertson JF; Cheung KL
Breast; 2014 Oct; 23(5):567-72. PubMed ID: 24874285
[TBL] [Abstract][Full Text] [Related]
13. Patterns of breast cancer relapse in accordance to biological subtype.
Ignatov A; Eggemann H; Burger E; Ignatov T
J Cancer Res Clin Oncol; 2018 Jul; 144(7):1347-1355. PubMed ID: 29675790
[TBL] [Abstract][Full Text] [Related]
14. [Modified breast cancer after care].
Jäger W; Merkle E; Tulusan AH; Lang N
Gynakol Rundsch; 1991; 31 Suppl 2():296-9. PubMed ID: 1665139
[No Abstract] [Full Text] [Related]
15. Luminal subtypes predict improved survival following central nervous system metastasis in patients with surgically managed metastatic breast carcinoma.
Wiens AL; Martin SE; Bertsch EC; Vance GH; Stohler RA; Cheng L; Badve S; Hattab EM
Arch Pathol Lab Med; 2014 Feb; 138(2):175-81. PubMed ID: 24476516
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of clinical parameters influencing the development of bone metastasis in breast cancer.
Diessner J; Wischnewsky M; Stüber T; Stein R; Krockenberger M; Häusler S; Janni W; Kreienberg R; Blettner M; Schwentner L; Wöckel A; Bartmann C
BMC Cancer; 2016 May; 16():307. PubMed ID: 27175930
[TBL] [Abstract][Full Text] [Related]
17. Tumor markers in the early detection of tumor recurrence in breast cancer patients: CA 125, CYFRA 21-1, HER2 shed antigen, LDH and CRP in combination with CEA and CA 15-3.
Di Gioia D; Blankenburg I; Nagel D; Heinemann V; Stieber P
Clin Chim Acta; 2016 Oct; 461():1-7. PubMed ID: 27451906
[TBL] [Abstract][Full Text] [Related]
18. Comparison of bone scanning and CA 15-3 serum concentration in the follow-up of breast cancer.
Montravers F; Younsi N; Rousseau C; Philippe C; Seddiki M; Uzan S; Izrael V; Talbot JN
Anticancer Res; 1997; 17(3B):1683-6. PubMed ID: 9179218
[TBL] [Abstract][Full Text] [Related]
19. Comparison of Predictive Immunohistochemical Marker Expression of Primary Breast Cancer and Paired Distant Metastasis using Surgical Material: A Practice-Based Study.
Kulka J; Székely B; Lukács LV; Kiss O; Tőkés AM; Vincze E; Turányi E; Fillinger J; Hanzély Z; Arató G; Szendrői M; Győrffy B; Szász AM
J Histochem Cytochem; 2016 Apr; 64(4):256-67. PubMed ID: 27029768
[TBL] [Abstract][Full Text] [Related]
20. [Evaluation and performance of the follow-up in treated cancer of the breast].
Villet R; Van Den Akker M; Ulliac T; Benbunan JL; Scali P
Rev Fr Gynecol Obstet; 1993 Feb; 88(2):98-103. PubMed ID: 8469875
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
